Imv Inc (IMV) Given Average Rating of “Buy” by Brokerages

Shares of Imv Inc (NYSE:IMV) have been given a consensus broker rating score of 1.58 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating on the company. IMV’s rating score has declined by 10.5% in the last three months as a result of a number of analysts’ ratings changes.

Brokerages have set a 1 year consensus price objective of $10.31 for the company and are anticipating that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also given IMV an industry rank of 63 out of 256 based on the ratings given to related companies.

Separately, Raymond James set a $10.00 price objective on shares of IMV and gave the stock an “outperform” rating in a report on Thursday, November 22nd.

A number of hedge funds have recently made changes to their positions in the business. FIL Ltd grew its holdings in IMV by 0.9% during the 3rd quarter. FIL Ltd now owns 2,700,000 shares of the company’s stock worth $15,845,000 after acquiring an additional 25,000 shares in the last quarter. Prentiss Smith & Co. Inc. boosted its holdings in shares of IMV by 1,929.0% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 44,374 shares of the company’s stock valued at $264,000 after buying an additional 42,187 shares during the period. First Manhattan Co. acquired a new position in shares of IMV in the 3rd quarter valued at about $522,000. Finally, Renaissance Technologies LLC acquired a new position in shares of IMV in the 2nd quarter valued at about $230,000.

IMV stock opened at $5.38 on Wednesday. IMV has a 12-month low of $4.40 and a 12-month high of $7.21.

IMV (NYSE:IMV) last released its quarterly earnings results on Friday, November 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.04). The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.05 million.

About IMV

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on IMV (IMV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit